Donepezil shows short-term benefit in slowing MCI progression to AD; vitamin E use has little advantage
Publish date: October 1, 2004
Donepezil therapy, compared to placebo, may reduce the rate of progression to Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI), according to Ronald Petersen, MD, PhD, of the Mayo Clinic in Rochester, Minn., who presented data at the Alzheimer's conference. The study found no apparent benefit from use of vitamin E.